The development and assessment of a fluorescence-labelled immunosorbent assay for the detection of antibodies to the human immunodeficiency virus is described.
The acquired immune deficiency syndrome (AIDS) was first recognised in 1981 as a fatal disorder of cell mediated immunity. I The causative agent of AIDS is a virus 2 • 3 now called HIV 4 (human immunodeficiency virus), but previously referred to as HTLV-3 (human T cell lymphotropic virus type 3) or LAV (lymphadenopathy-associated virus). The main transmission modes of the virus are sexual contact and exposure to infected blood or blood products.
Tests for detecting infection by HIV are of particular value in studying the spread of the epidemic, as an aid to the diagnosis of AIDS and in screening blood to avoid the use of donations from infected people. Since HIV may be transmitted by blood transfusion and by some blood products (for example, Factor VIII used to treat haemophilia) the testing of all Correspondence: Dr B FRocks. 522 donations has become a necessity. The National Blood Transfusion Service needs to test more than 2 million units of blood per year. In addition, the Public Health Laboratory Service and other hospital laboratories are carrying out an estimated 30()()()() tests per annum.
Unequivocal proof that blood is infected would require recovery of the virus from T4+ lymphocytes. Although techniques have been developed for detecting the presence of the viral antigens the procedures are complex, laborious and require relatively long incubation periods. Though virus culture is useful in that it allows the examination of the genomic diversity of the virus the technique is not well suited for routine use in a clinical laboratory.! Tests currently used to evaluate patients and blood donors for exposure to HIV rely upon detection of specific antibody.
Following identification of the virus in 1983 6 and the discovery of a cell line (leukaemic T helper-lymphocytes) which could support in vitro propagation 7 the virus was harvested in sufficient quantities to enable tests for antibodies to be developed. The diagnostics industry reacted remarkably quickly and by mid 1985 several anti-HIV enzyme-linked immunosorbent assay2. 8. 9 (ELISA) kits were commercially available. Following a Department of Health and Social Security-sponsored evaluation of five kits'" II the National Blood Transfusion Service began screening donated blood from October 1985. By early 1986 many hospital laboratories offered anti-HIV testing as part of their routine diagnostic service.
In addition to the widely used commercially available ELISAs other methods of detecting anti-HIV are available." Several of these have been developed as 'in house' assays and are of particular value in helping with equivocal results. For example, immunofluorescence.P radioimmunoassay?' 13 and Western blotting" have been described.
Compared with other test formats ELISA, usually with microtitre wells, has the advantage of being technically simple to carry out and of being relatively inexpensive. Consequently, almost all primary testing is done using ELiSAs.
However, several problems are associated with the use of enzymes (usually, horseradish peroxidase) as labels. In addition to the immunological part of the protocol, enzyme labelled assays require an extra step in which the tests are incubated with enzyme substrate reagent in order to produce a coloured product. The colour reaction is allowed to proceed for a measured time and the reaction is stopped with a strong mineral acid and the colour read photometrically. The step required for determining the enzyme activity is prone to errors and adds significantly to the time needed to produce results. Other disadvantages of ELISA result from the bulky, labile nature of the enzyme label and its susceptibility to inhibition and denaturation. The narrow dynamic range in photometric measurement also limits the dynamic range of ELISAs based on colorimetry.
We report the development and preliminary evaluation of a solid-phase-based immunofluorometric anti-globulin assay using microtitre wells for detecting and quantifying antibodies to HIV. By analogy with ELISA, we refer to it as a fluorescence-labelled immunosorbent assay (FLISA). Since an enzyme reaction is not involved the assay is quicker and less prone to errors than an equivalent ELISA.
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Materials and methods Except where otherwise stated laboratory reagents were obtained from BDH Chemicals Ltd, Poole, Dorset, UK. Commercially available ELISA kits-the Vironostika anti-HTLV-III Microelisa System-were supplied by Organon Teknika Ltd, Milton Road, Cambridge. This particular product was chosen because it was in routine use by our PHLS laboratory; and because in trials against other commercial kits it was found to be both sensitive and specific, and was recommended as being one of the most suitable for use in clinical Iaboratories.l'" 11. 15 Antigen-coated microtitre well strips and normal goat serum were obtained from the Organon kits.
SPECIMENS
In order to assess the new assay we compiled a panel of samples consisting of known anti-HfV positives and negatives. The negative serum samples were obtained from specimens sent to our laboratory for tests other than anti-HIV testing. The positives were from patients being investigated or treated for HIV infection, persistent generalised lymphadenopathy, AIDS related complex or AIDS. As a preliminary to this study all the samples in our panel were tested and categorised as being either positive or negative. This involved screening by a commercial ELISA kit and confirmation of positive results by the Virus Reference Laboratory (Colindale Avenue, London) using complementary tests (for example, a noncommercial radioimmunoassay':'). The Central Public Health Laboratory Division of Microbiological Reagents and Quality Control (DMRQC) supplied us with six recalcified plasma controls (panel no. 8) consisting of five positives, prepared by diluting a high titre positive specimen, and a negative. Another DMRQC control preparation (designated LP3), which was a.positive sample diluted to the point where it gave neither a strong positive or negative reading, Was used as our 'reference serum'. Plasma or serum was heat treated at 56°C for 30 min and stored at -200C prior to use.
ELISAS
The enzyme labelled tests were carried out according to the manufacturer's instructions, except where otherwise stated.
PRINCIPLE OF THE FLiSA
Test serum is incubated in microtitre wells on which antigens (i.e. disrupted viral particles derived from infected lymphocytes, HT/H9/3 cell line) have been coated. Any anti-HIV present in the serum will bind to the solid-phase antigen. Following serum removal and appropriate washing, goat anti-human immunoglobulin labelled with fluorescein is added and the test reincubated. During this step the labelled conjugate combines with any solidphase antigenlanti-HIV complex previously formed.
After removal of unbound conjugate, by washing of the wells, bound conjugate is freed by adding acid and following the addition of a buffer (pH 9,7) the fluorescence of the solution in each well is read. The fluorescence of the final solution is proportional to the amount of anti-HIV binding to the solid-phase antigens. If the sample contains no anti-HI V the labelled conjugate cannot be bound and only a slight background fluorescence is observed. Positive specimens produce an intense fluorescence. Test samples are graded by comparison to a reference control.
FLISA PROCEDURE
Fifty microlitres of phosphate buffered saline, PBS,·(0·14 M NaCl, 2·7 mM KC1, 1·5 mM KH 2P04, 8·1 mM Na2HP04, pH 7·3) containing 10% of normal goat serum and 0·5% Tween 20 was added to each well. After a minimum of 3 min 50 !4L of the test serum was added. The wells were sealed with masking tape and agitated for 10 s to mix the solution. Reference serum was used in 2 wells in each 12 well strip. The wells were incubated at 37°C for 15 min and then washed 5 times with 300 !4L PBS.
Two microgrammes of goat anti-human immunoglobulin labelled with fluorescein isothiocyanate (Sigma Chemical Co. Ltd, Poole, Dorset, UK) in 100 !4L of PBS containing 0·5% Tween 20 was added to each well; the wells were sealed, agitated for 10 s, and then incubated at 37°C for 15 min, followed by washing 5 times with 300 !4L of PBS containing 0·1% Tween 20.
One hundred microlitres of 0·1 N HCl was added to each well, and after agitation for 3 min, 200 !4L of 1M K 2HP04 was added to each. The wells were sealed and mixed by inversion.
The fluorescence was measured by aspirating the contents of each well through a flow cell contained in a Perkin-Elmer MPF-3L spectrofluorimeter (Perkin-Elmer Ltd, Beaconsfield, Bucks, UK). Instrument settings were: excitation wavelength 485 nm, bandwidth 20 nm; emission wavelength 530 nm, bandwidth 20 rim; instrument sensitivity 20.
FLISA DEVELOPMENT
Although there are at least a dozen anti-HIV kits commercially available in the UK there is a paucity of published details regarding the reaction conditions and the composition of the various reagents. We carried out experiments to study the effects of variables on the two timeconsuming incubation stages. It was our aim to design a batch assay capable of producing results in as short a time as possible. Some of our observations are summarised below.
Anti-HIV/antigen reaction Neat serum was diluted by adding it to microwells containing an equal volume of buffer. Goat serum in the buffer was necessary to prevent non-specific binding, however, it also decreased the rate of reaction. We found that by adding the buffer containing goat serum before the test serum (at least 3 min) nonspecific binding was prevented using a lower concentration (5%) of goat serum than would otherwise be needed. Addition of Tween 20 (0·1--0·5%) to the buffer solution increased the rate of reaction.
Decreasing the reaction time from 30 to 15 min produced no decrease in fluorescence values. It may be possible to decrease the reaction time further but this has not been investigated; the need for precise timing between manually loading each well and reading it makes very short incubation periods difficult to cope with.
Increasing the incubation temperature from 37°C to 45°C decreased the fluorescence and the results were less reproducible; consquently. a temperature of 3TC was chosen for this stage of the assay.
Anti-HIV/conjugate reaction
The time required to reach maximum fluorescence depends on the anti-HIV titre of the serum. The labelled anti-human immunoglobulin binds rapidly with antibodies in high-titre and there was no difference between using incubation periods of 5, 10, 15 and 30 min. Low positive serum samples need about 10 min to achieve maximum binding while negative samples produced a slight, gradual increase in binding with time, at least over the 30 min of our study. We chose to work with an incubation time of 15 min as it gave the best discrimina-tion .between posuwe and negative serum. Addition of goat serum to the buffer increased non-specific binding. whereas addition of Tween 20 (0·5%) decreased it. Raising the temperature at this stage to 45°C gave inconsistent results so 37°C was used. Fluorescence values reached a maximum when I ug of conjugate was added to each well.
Removal of the conjugate
Different reagents for removing the fluorescent conjugate from the microwells were tested: O·IM NaOH; O·IM HCI; O·IM glycine/HCl. pH 2·5: and 1M propionic acid. Of these O·IM HCI was not only the fastest. but also gave the most consistent results. Addition of 1M K 2 HP0 4 was then necessary to bring the pH into the range of maximum fluorescence of fluorescein. Tween 20 was not used in these reagents since its presence caused the formation of microbubbles which caused errors in the fluorescent measurements.
Results
Presentation of results takes into account four aspects of FLISA: specificity. sensitivity. reproducibility. and comparison with a commercial anti-IIIV ELISA. 30 
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An evaluation panel consisting of 70 samples comprising 29 negative. 34 positive. six DMRQC controls and a reference serum were tested by the FLISA procedure. One sample that gave a discrepant result was retested. The distribution of results relative to the weight of fluorescent conjugate released from the wells. estimated by comparison to standard solutions of conjugate. is shown in Fig. I . There is a clear distinction between normal and positive results.
In Fig. 2 the same results are presented in terms of the ratio: sample fluorescencel reference fluorescence. This method of reporting is analogous to that used in a recent evaluation of six commercial anti-HIV test kits. 15 The SIR ratio is equal to I when the fluorescence of the test sample equals the fluorescence produced by the reference sera.
Positive and negative serum samples fell into two clearly discernible groups with none of the tested samples falling into the divisions on either side of the reference serum. For negative serum the mean SIR was 0·21. and for the positives the mean SIR was 3·64. Of the 39 positive samples. 85% had a fluorescence ratio greater than 2 and all had a ratio greater than 1·4. Of the 30 negative samples. 29 had a ratio less than 0·8 on first testing. It might. therefore. be reasonable to classify results with a ratio of o less than O·M as negative; results with a ratio greater than 1·4 as being positive and to retest results with ratios of between O·S and 1·4. One negative sample originally fell into this 'equivocal' area (ratio 1·40), but on retesting it was found to have a ratio of 0·79. (In the absence of an obvious explanation for this discrepancy we assume that the first higher than expected reading resulted from scatter of the excitation light beam; caused, perhaps, by a small air bubble.) If we define sensitivity of the FLiSA as the proportion of positive and samples correctly identified then the test has a sensitivity of 100%; and if assay specificity is defined as the proportion of negatives correctly identified then on first testing the specificity was 96·7%. and 100% on retesting. A positive serum and a negative serum were repeatedly tested 16 times and in every case the samples were correctly categorised. The within batch fluorescence readings for the reference serum had a coefficient of variation of 12·1% (n = 16). suits were 200 for one sample and 800 for the other-, The relationship between fluorescence and dilution for the higher titre serum is shown in Fig. 3 . As can be seen the slope of the curve is steepest at high sample dilutions. This gives maximum sensitivity for the detection of serum with very low antibody titres.
COMPARISON WITH ELISA
In principle the Organon Teknica ELISA is similar to the FUSA except that horseradish peroxidase-labelled goat anti-human immunoglobulin is used to estimate the solid phase bound antigen/anti-HIV complex. The enzyme activity is measured with substrate solution containing urea peroxide and o-phenylenediamine. After a 30 min incubation period the enzyme reaction is stopped by the addition of acid and the absorbance of the solution in each well is read at 492 nm.
There was 100% agreement between the FLISA and the Organon ELISA on.the allocation of the evaluation panel samples into positive and negative categories. Analytical sensitivity was also similar. The ratio of the mean of the positive to the mean of the negative samples for the FLISA was 17·3, and 8·1 for the ELISA.
Since the samples in our panel fell at the extremes of the measuring range of the assays, we diluted 13 positive samples to give a more scattered range of results. These were tested together with 14 positive and 10 negative samples by both the ELISA and the FLISA.
Because positive serum, when tested with the ELISA, frequently produced absorbances greater than 2 we diluted the final coloured solution 1:5 and read the absorbances in a spectrophotometer at 492 nm. A comparison of results obtained in this way is illustrated in Fig.  4 . The Pearson correlation coefficient, r,=0·89.
Discussion
Enzyme labels became available in the early 1970's and they are now the most frequently used alternative to radiolabels in immunoassay. 16 Nearly all anti-HIV screeninf is carried out using commercial ELISA kits.' Enzymes are not, however, ideal labels. The extra step required for the enzyme reaction adds to the complexity of the test and further increases the chance of technical error. Traces of metals may cause inaccuracies and colour development can be influenced by exposure to strong light.
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Additionally, some enzyme substrate reagents are known to be mutagenic.
The delay caused by the enzyme incubation adds significantlyto the time needed to produce results. There are several situations where a more rapid anti-HIV test would be advantageous. For example, in accident and emergency departments, in transplant units and in the preparation of factor VIII. Because of the labile nature of factor VIII speed of extraction from freshly donated blood is crucial. Many units of plasma from different donors are pooled and processed before the test results are known. If an anti-HIV positive is subsequently discovered to have been added to the mix the whole batch must of course be discarded. This waste could be reduced if the individual donations could be quickly tested prior to pooling them. It was primarily to meet these needs that we developed the FLISA.
As with all anti-HIV test procedures the sensitivity and specificity of the FLISA is influenced by the chosen level of the cut-off values; unfortunately, there are no 'gold standards'. As the threshold for defining the minimum positive FLISA ratio decreases, the sensitivity of the assay in detecting weak anti-HIV cases increases, while the specificity decreases. Since positive results found by a screening test would normally be confirmed by several other tests of different formats it is best to bias the cut-off towards producing false positives rather than false negatives. For example, for the present FLISA we would suggest a cut-off ratio of 0·8 for use in blood screening. At this ratio the cut-off should not unneccessarily exclude large quantities of donated blood.
On the basis of the panel of sera studied the sensitivity and specificity of the FLISA was high. The correlation coefficient, r, between the FLISA and the ELISA was 0·89 (n=37). Most comparisons of anti-HIV kits have been concerned only with the ability of the tests to distinguish positive from negative sera and correlation coefficientshave not been published. In the one study where coefficients of correlation have been reported," out of eight ELISA kits studied, the best correlation was 0·88 and the worst 0·5. Kits from Organon and Sorin, which use antigens from a common source, gave the best agreement.
Compared with the ELISA from which it was derived the FLISA offers a considerable saving in assay time. With the FLISA there is no need for sample predilution, the incubation stages are shorter, and the enzyme reaction stage has Table. The problem with fluorescent labels in biological assays has been their inferior sensitivity caused, to a large extent, by the high background of the fluorescent measurement. However, the use of solid-phase immunosorbent assays avoids problems of background fluorescence from serum. Fluorescein was chosen as our fluorophore because of its high quantum yield and because immunoglobulin conjugates are commercially available. However, labels with small Stokes shifts (the difference between the wavelengths of the excitation and emission maxima), such as fluorescein, are particularlary susceptible to interference by scattered light. In this respect occasional microbubbles in the flow cell proved to be troublesome and consequently we are currently investigating other fluorophores with larger Stokes shifts. 19 We conclude that we have demonstrated the feasibilityof testing for anti-HN by the use of a fluorescence-labelled immunoassay. The sensitivity and specificity for correctly identifying positive sera, from infected patients, are extremely high. The FLISA could form the basis for the development of a rapid screening assay for use by the National Blood Transfusion Service.
